Profile data is unavailable for this security.
About the company
Therma Bright Inc. is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. The Venowave is a medical compression pump that is lightweight, compact, battery operated, designed to treat and alleviate the symptoms associated with poor circulation.
- Revenue in CAD (TTM)25.80k
- Net income in CAD-2.88m
- Incorporated2018
- Employees--
- LocationTherma Bright Inc132-1173 Dundas Street EastTORONTO M4M 3P1CanadaCAN
- Phone+1 (416) 867-2353
- Fax+1 (416) 867-4566
- Websitehttps://thermabright.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rakovina Therapeutics Inc | 0.00 | -2.72m | 7.71m | -- | -- | 2.62 | -- | -- | -0.039 | -0.039 | 0.00 | 0.042 | 0.00 | -- | -- | -- | -53.46 | -- | -56.12 | -- | -- | -- | -- | -- | -- | -16.52 | 0.3151 | -- | -- | -- | 6.39 | -- | -- | -- |
XORTX Therapeutics Inc | 0.00 | -4.59m | 7.84m | 3.00 | -- | 2.29 | -- | -- | -1.93 | -1.93 | 0.00 | 1.18 | 0.00 | -- | -- | -- | -42.59 | -35.42 | -45.30 | -40.37 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 72.04 | -- | 7.91 | -- |
Therma Bright Inc | 25.80k | -2.88m | 7.90m | -- | -- | 4.31 | -- | 306.12 | -0.0115 | -0.0115 | 0.0001 | 0.0058 | 0.0076 | 0.0023 | 0.115 | -- | -84.40 | -220.66 | -165.23 | -444.57 | 98.45 | -- | -11,152.48 | -10,853.16 | 0.0447 | -184.52 | 0.0411 | -- | -82.86 | 11.13 | 35.93 | -- | 40.15 | -- |
Crescita Therapeutics Inc | 17.92m | -2.34m | 8.38m | 78.00 | -- | 0.4631 | -- | 0.4676 | -0.1162 | -0.1162 | 0.8927 | 0.9285 | 0.6903 | 1.50 | 4.62 | -- | -9.01 | -0.2457 | -11.40 | -0.3059 | 56.03 | 63.41 | -13.06 | -0.3518 | 2.60 | -- | 0.0594 | -- | -25.52 | 1.05 | -330.39 | -- | -1.58 | -- |
Khiron Life Sciences Corp | 16.14m | -30.66m | 9.30m | 310.00 | -- | -- | -- | 0.5761 | -0.1674 | -0.1674 | 0.085 | 0.1248 | 0.3078 | 1.33 | 3.90 | 52,055.68 | -58.47 | -- | -69.10 | -- | 19.51 | -- | -190.00 | -- | 0.9133 | -- | 0.0864 | -- | 59.60 | -- | -37.81 | -- | -- | -- |